Human Growth Hormone Market Analysis Overview:
In a recent research report by Markert Research Community, the human growth hormone market is expected to surpass USD 12.29 Billion by the year 2030, from USD 5.80 Billion in 2021.
The market is projected to develop at a huge speed arriving at a CAGR of approximately 8.7%, over the gauge time of 2022-2028, notwithstanding an extensive fall in item deals during the underlying period of pandemic spread and lockdown limitations imposed universally.
Growth hormone is produced by the pituitary gland. The hypothalamus in the brain communicates with the pituitary gland to create GH, which then circulates through the bloodstream to work in various areas of the body. The epiphyseal growth plates in the bone, which are in charge of bone elongation, are stimulated by GH.
Top Key Players of the Human Growth Hormone Market:
The report includes a regional analysis and country analysis with the latest trends, along with the major key players including Novo Nordisk A/S; Pfizer, Inc; Eli Lilly and Company; Sandoz International GmbH (Novartis AG); Merck KGaA; Genentech, Inc (Roche); Ferring Pharmaceuticals; Teva Pharmaceutical Industries, Ltd; Ipsen.
In addition, GH stimulates the production of the protein known as insulin-like growth factor-I (IGF-I), which in turn controls the release of GH from the pituitary and stimulates the growth of bone, muscle, and other tissues in response to Growth Hormone.
On the Basis of Application:
Growth Hormone (GH) Deficiency,
Adult GH Deficiency,
Pediatric GH Deficiency,
Turner Syndrome
Idiopathic Short Stature
Prader-Willi Syndrome
Small for Gestational Age
Other
Regional Analysis:
North America– (U.S., Canada, Mexico)
Europe- (Germany, France, U.K., Russia, Italy, Spain, BENELUX, Rest of Europe)
Asia Pacific- (China, Japan, India, South Korea, Australia, ASEAN, Rest of Asia Pacific)
Latin America- (Brazil, Argentina, Chile, Rest of Latin America)
Middle East and Africa- (GCC, Turkey, Israel, Rest of MEA)
The online pharmacy market is anticipated to grow significantly over the projected period due to the widespread distribution of pharmacies in developed nations like North America and Europe. In addition, the growing popularity of online pharmacies in developing nations like China and India is anticipated to fuel segment expansion in the ensuing years.
Throughout the forecast period, Asia Pacific is anticipated to have a considerable CAGR. By obtaining clearance and launching innovative products, a large market share in potential Asia Pacific nations like China and Japan is a goal for major firms. For instance, the phase III clinical trial of the pharmaceutical company Novo Nordisk A/HGH S's somapacitan, which is indicated for the treatment of adult growth hormone insufficiency, was started in Japan in March 2017.
The study is consolidated into major segments and further into sub-segments, such as by Application (Growth Hormone (GH), Pediatric GH Deficiency, Turner Syndrome, Idiopathic Short Stature, Human Growth Hormone Market Industry, Prader-Willi Syndrome, Small for Gestational Age, Other), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Specialty Pharmacy), to forecast the size by value; also includes the analysis of past dynamics from 2016 – 2021, considering 2021 as the base year.
The research provides answers to the following key questions:
- What is the expected growth rate of the Human Growth Hormone Market? What will be the market size for the forecast period, 2022 - 2030?
- What are the major driving forces responsible for transforming the trajectory of the industry?
- Who are major vendors dominating the Human Growth Hormone industry across different regions? What are their winning strategies to stay ahead in the competition?
- What are the market trends business owners can rely upon in the coming years?
- What are the threats and challenges expected to restrict the progress of the industry across different countries?
- What are the key opportunities that business owners can bank on for the forecast period, 2022 - 2030?
Contact:
